Enanta Pharmaceuticals Inc (ENTA) 43.23 $ENTA
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 104.13 (-0.18), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Insider Trading Alert - ENTA, A And BHB Traded By Insiders
at The Street - Wed Dec 03, 9:08AM CST
Stocks with insider trader activity include ENTA, A and BHB
A: 39.72 (-0.90), BHB: 31.00 (-0.10), ENTA: 43.23 (-3.20)
2nd Half Of 2014 Biotechnology Catalysts: Part 5
Alexander Maxwell - at Seeking Alpha - Mon Dec 01, 8:59AM CST
BCRX: 10.06 (+0.02), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), POZN: 9.12 (-0.08), ENTA: 43.23 (-3.20)
5 Stock-Moving Medtech Events This December
at Investor's Business Daily - Fri Nov 28, 1:18PM CST
December is usually a quiet month for medical tech news, but this year will bring a few potentially stock-moving events worth keeping an eye on. As you digest your Thanksgiving turkey, here are the top five in chronological order: By Dec. 5, biotech...
SNN: 32.48 (-0.41), ESRX: 82.88 (-1.10), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), INCY: 74.65 (-1.27), EW: 128.87 (-3.20), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Very Exciting Days Are In Store For Enanta Stockholders
George Rho - at Seeking Alpha - Thu Nov 27, 9:00AM CST
ENTA: 43.23 (-3.20)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 91.28 (+5.16), OREX: 5.74 (-0.02), BCRX: 10.06 (+0.02), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Company News for November 25, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:10AM CST
Companies in the News are: DDD,TSL,ENTA,LMT
LMT: 185.18 (-4.07), DDD: 30.00 (-0.59), TSL: 8.82 (-0.30), ENTA: 43.23 (-3.20)
Enanta Pharmaceutical's (ENTA) CEO Jay Luly on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 24, 5:05PM CST
ENTA: 43.23 (-3.20)
Can Partnering To Fight Hepatitis C Pay At Enanta?
at Investor's Business Daily - Mon Nov 24, 3:44PM CST
Biotech company Enanta Pharmaceuticals has been around for 19 years, but the fiscal year it's entering now is surely the most important one of its life. By Dec. 21, the Food and Drug Administration is expected to approve AbbVie's (ABBV) Viekirax, a...
GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Chip Stocks, Biotechs Lead Another Nasdaq Rally
at Investor's Business Daily - Mon Nov 24, 1:58PM CST
Chip stocks fueled a day of outperformance for the Nasdaq Monday. The composite was up 0.8% in afternoon trading, buoyed by strength in Nasdaq 100 chip names like KLA-Tencor (KLAC), NXP Semiconductors (NXPI), SanDisk (SNDK) and Intel (INTC). The S&P...
NXPI: 73.39 (-1.56), INTC: 36.22 (-0.48), ENTA: 43.23 (-3.20), FIVE: 37.39 (+0.24), PANW: 118.07 (-0.84), CELG: 114.49 (-2.25), QIHU: 60.22 (+0.32), MDVN: 106.86 (-1.16), LCI: 43.58 (-0.46), WDAY: 81.58 (-1.40), KLAC: 68.63 (-0.52), SNDK: 98.79 (-2.94)
Enanta Pharma ups revenues 100% in FQ4
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 7:06AM CST
ENTA: 43.23 (-3.20)
Enanta Pharmaceuticals beats 4Q profit forecasts
Automated Insights - Mon Nov 24, 6:51AM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported a loss of $5 million in its fiscal fourth quarter.
ENTA: 43.23 (-3.20)
Enanta beats by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 6:36AM CST
ENTA: 43.23 (-3.20)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2014
Business Wire - Mon Nov 24, 6:30AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal fourth quarter and year ended September 30, 2014.
ENTA: 43.23 (-3.20)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 23, 4:30PM CST
NM: 3.73 (-0.12), DCIX: 2.11 (+0.01), TSL: 8.82 (-0.30), ENTA: 43.23 (-3.20)
AbbVie, Celgene, Sanofi Drugs Get EU Endorsements
at Investor's Business Daily - Fri Nov 21, 11:28AM CST
The European Union's medical advisory committee endorsed approving key products for three major drugmakers Friday, two of them expected to be blockbusters. AbbVie (ABBV) got the thumbs up for its all-oral hepatitis C combo, which now has brand names....
GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ENTA: 43.23 (-3.20), CELG: 114.49 (-2.25)
Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST
Business Wire - Fri Nov 21, 8:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat, or question and answer session, with investors December 1, 2014 at 10:25 a.m. ET during the Deutsche Bank 2014 BioFEST conference in Boston.
ENTA: 43.23 (-3.20)
European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST
GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Enanta Announces CHMP Grants Positive Opinions of AbbVie's VIEKIRAX(TM) (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA(TM) (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
Business Wire - Fri Nov 21, 7:09AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX(TM) (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA(TM) (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX(TM) only, with RBV, for patients with genotype 4 (GT4) HCV infection. AbbVie anticipates that the European Commission will review the opinions and make a final decision sometime in the first quarter of 2015.
ENTA: 43.23 (-3.20)
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 104.13 (-0.18), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Insider Trading Alert - ENTA, A And BHB Traded By Insiders
at The Street - Wed Dec 03, 9:08AM CST
Stocks with insider trader activity include ENTA, A and BHB
A: 39.72 (-0.90), BHB: 31.00 (-0.10), ENTA: 43.23 (-3.20)
2nd Half Of 2014 Biotechnology Catalysts: Part 5
Alexander Maxwell - at Seeking Alpha - Mon Dec 01, 8:59AM CST
BCRX: 10.06 (+0.02), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), POZN: 9.12 (-0.08), ENTA: 43.23 (-3.20)
5 Stock-Moving Medtech Events This December
at Investor's Business Daily - Fri Nov 28, 1:18PM CST
December is usually a quiet month for medical tech news, but this year will bring a few potentially stock-moving events worth keeping an eye on. As you digest your Thanksgiving turkey, here are the top five in chronological order: By Dec. 5, biotech...
SNN: 32.48 (-0.41), ESRX: 82.88 (-1.10), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), INCY: 74.65 (-1.27), EW: 128.87 (-3.20), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Very Exciting Days Are In Store For Enanta Stockholders
George Rho - at Seeking Alpha - Thu Nov 27, 9:00AM CST
ENTA: 43.23 (-3.20)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 91.28 (+5.16), OREX: 5.74 (-0.02), BCRX: 10.06 (+0.02), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Company News for November 25, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:10AM CST
Companies in the News are: DDD,TSL,ENTA,LMT
LMT: 185.18 (-4.07), DDD: 30.00 (-0.59), TSL: 8.82 (-0.30), ENTA: 43.23 (-3.20)
Enanta Pharmaceutical's (ENTA) CEO Jay Luly on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 24, 5:05PM CST
ENTA: 43.23 (-3.20)
Can Partnering To Fight Hepatitis C Pay At Enanta?
at Investor's Business Daily - Mon Nov 24, 3:44PM CST
Biotech company Enanta Pharmaceuticals has been around for 19 years, but the fiscal year it's entering now is surely the most important one of its life. By Dec. 21, the Food and Drug Administration is expected to approve AbbVie's (ABBV) Viekirax, a...
GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Chip Stocks, Biotechs Lead Another Nasdaq Rally
at Investor's Business Daily - Mon Nov 24, 1:58PM CST
Chip stocks fueled a day of outperformance for the Nasdaq Monday. The composite was up 0.8% in afternoon trading, buoyed by strength in Nasdaq 100 chip names like KLA-Tencor (KLAC), NXP Semiconductors (NXPI), SanDisk (SNDK) and Intel (INTC). The S&P...
NXPI: 73.39 (-1.56), INTC: 36.22 (-0.48), ENTA: 43.23 (-3.20), FIVE: 37.39 (+0.24), PANW: 118.07 (-0.84), CELG: 114.49 (-2.25), QIHU: 60.22 (+0.32), MDVN: 106.86 (-1.16), LCI: 43.58 (-0.46), WDAY: 81.58 (-1.40), KLAC: 68.63 (-0.52), SNDK: 98.79 (-2.94)
Enanta Pharma ups revenues 100% in FQ4
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 7:06AM CST
ENTA: 43.23 (-3.20)
Enanta Pharmaceuticals beats 4Q profit forecasts
Automated Insights - Mon Nov 24, 6:51AM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported a loss of $5 million in its fiscal fourth quarter.
ENTA: 43.23 (-3.20)
Enanta beats by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 6:36AM CST
ENTA: 43.23 (-3.20)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2014
Business Wire - Mon Nov 24, 6:30AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal fourth quarter and year ended September 30, 2014.
ENTA: 43.23 (-3.20)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 23, 4:30PM CST
NM: 3.73 (-0.12), DCIX: 2.11 (+0.01), TSL: 8.82 (-0.30), ENTA: 43.23 (-3.20)
AbbVie, Celgene, Sanofi Drugs Get EU Endorsements
at Investor's Business Daily - Fri Nov 21, 11:28AM CST
The European Union's medical advisory committee endorsed approving key products for three major drugmakers Friday, two of them expected to be blockbusters. AbbVie (ABBV) got the thumbs up for its all-oral hepatitis C combo, which now has brand names....
GILD: 104.13 (-0.18), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ENTA: 43.23 (-3.20), CELG: 114.49 (-2.25)
Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST
Business Wire - Fri Nov 21, 8:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat, or question and answer session, with investors December 1, 2014 at 10:25 a.m. ET during the Deutsche Bank 2014 BioFEST conference in Boston.
ENTA: 43.23 (-3.20)
European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST
GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Enanta Announces CHMP Grants Positive Opinions of AbbVie's VIEKIRAX(TM) (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA(TM) (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
Business Wire - Fri Nov 21, 7:09AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX(TM) (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA(TM) (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX(TM) only, with RBV, for patients with genotype 4 (GT4) HCV infection. AbbVie anticipates that the European Commission will review the opinions and make a final decision sometime in the first quarter of 2015.
ENTA: 43.23 (-3.20)
